REDWOOD CITY, Calif., April 25 /PRNewswire-FirstCall/ -- Threshold Pharmaceuticals, Inc. , today announced that the Company will make presentations at the following investor conferences:
6th Annual Fortis Bank Biotechnology Conference, London, UK Wednesday, April 26th 2:15 p.m. GMT Michael Ostrach, Chief Operating Officer Morgan Stanley Global Healthcare Unplugged Conference, Miami, FL Thursday, May 4th 10:30 a.m. EDT Barry Selick, Chief Executive Officer RW Baird 2006 Growth Stock Conference, Chicago, IL Tuesday, May 9th 9:05 a.m. CDT Michael Ostrach, Chief Operating Officer Rodman & Renshaw 3rd Annual Global Healthcare Conference, Monaco Monday, May 15th 12:40 p.m. CEST Michael Ostrach, Chief Operating Officer Banc of America 2006 Healthcare Conference, Las Vegas, NV Tuesday, May 16th 4:40 p.m. PDT Barry Selick, Chief Executive Officer About Threshold Pharmaceuticals, Inc.
Threshold is a biotechnology company focused on the discovery, development and commercialization of small molecule therapeutics in middle- and late- stage clinical trials for the potential treatment of benign prostatic hyperplasia (BPH), a disease afflicting tens of millions of men worldwide, and cancer. By selectively targeting tumor or other abnormally-proliferating cells, the Company's drug candidates are designed to be potentially more effective and less toxic to healthy tissues than conventional treatments. For additional information, please visit our website: http://www.thresholdpharm.com.
Forward-Looking Statements
Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Threshold's product candidates, clinical trial progress and results, and potential therapeutic uses and benefits of our product candidates. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to complete its anticipated clinical trials, the time and expense required to conduct such clinical trials, and the results of such clinical trials (including unanticipated product safety issues as well as efficacy results). Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Annual Report on Form 10-K, which was filed with the Securities Exchange Commission on March 28, 2006 and is available from the SEC's website (www.sec.gov) and on our website (www.thresholdpharm.com) under the heading "Investors." We undertake no duty to update any forward-looking statement made in this news release.
Contact: Denise T. Powell Sr. Director, Corporate Communications Threshold Pharmaceuticals, Inc. 650-474-8206 dpowell@thresholdpharm.com Carolyn Bumgardner Wang WeissComm Partners, Inc. 415-946-1065 carolyn@weisscommpartners.com
Threshold Pharmaceuticals, Inc.CONTACT: Denise T. Powell, Sr. Director, Corporate Communications ofThreshold Pharmaceuticals, Inc., +1-650-474-8206, ordpowell@thresholdpharm.com; or Carolyn Bumgardner Wang of WeissCommPartners, Inc., +1-415-946-1065, or carolyn@weisscommpartners.com, forThreshold Pharmaceuticals, Inc.
Web site: http://www.thresholdpharm.com/